Geron shares jump on GE stem cell pact

This morning the share price of Geron shot up 23 percent after the biotech company announced that it is teaming up with GE Healthcare to develop embryonic stem cell products that researchers can use in drug discovery work and tox screening. No terms were announced, but the new partners said that they would be using cell lines available through the National Institutes of Health's Human Pluripotent Stem Cell Registry. Geron report